Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $28.00

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received a consensus recommendation of “Moderate Buy” from the fourteen research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $30.2727.

A number of research analysts have recently commented on BCAX shares. Wedbush reiterated an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Citizens Jmp restated a “market outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. The Goldman Sachs Group upped their target price on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Tuesday. Wells Fargo & Company upped their target price on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th.

Insider Transactions at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 17,392 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total value of $315,838.72. Following the completion of the transaction, the chief operating officer directly owned 205,141 shares in the company, valued at approximately $3,725,360.56. This represents a 7.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Raben sold 16,300 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total value of $301,876.00. Following the completion of the transaction, the insider owned 55,286 shares of the company’s stock, valued at $1,023,896.72. The trade was a 22.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 174,310 shares of company stock valued at $3,459,283. Company insiders own 15.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BCAX. Quantinno Capital Management LP raised its stake in Bicara Therapeutics by 16.1% during the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock worth $350,000 after acquiring an additional 2,447 shares in the last quarter. Orbimed Advisors LLC raised its stake in Bicara Therapeutics by 219.1% during the first quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock worth $13,273,000 after acquiring an additional 458,200 shares in the last quarter. Siren L.L.C. raised its stake in Bicara Therapeutics by 11.2% during the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after acquiring an additional 586,001 shares in the last quarter. Walleye Capital LLC acquired a new position in Bicara Therapeutics during the first quarter worth $2,148,000. Finally, Dimensional Fund Advisors LP raised its stake in Bicara Therapeutics by 166.9% during the first quarter. Dimensional Fund Advisors LP now owns 109,261 shares of the company’s stock worth $2,170,000 after acquiring an additional 68,327 shares in the last quarter.

Bicara Therapeutics Stock Down 2.0%

Shares of BCAX stock opened at $20.23 on Friday. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $24.25. The firm has a market cap of $1.33 billion, a PE ratio of -7.28 and a beta of -0.57. The stock has a 50 day moving average of $21.01 and a 200-day moving average of $18.19.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, equities analysts predict that Bicara Therapeutics will post -3.37 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.